MedPath

LEO LABORATORIES LIMITED

🇮🇪Ireland
Ownership
-
Employees
-
Market Cap
-
Website

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema

Phase 3
Completed
Conditions
Chronic Hand Eczema
Interventions
Drug: Cream vehicle
First Posted Date
2022-05-02
Last Posted Date
2025-01-23
Lead Sponsor
LEO Pharma
Target Recruit Count
98
Registration Number
NCT05355818
Locations
🇬🇧

LEO Pharma investigational site, Walsall, United Kingdom

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

Phase 2
Completed
Conditions
Frontal Fibrosing Alopecia
Interventions
First Posted Date
2022-04-18
Last Posted Date
2025-03-06
Lead Sponsor
LEO Pharma
Target Recruit Count
35
Registration Number
NCT05332366
Locations
🇺🇸

LEO Investigational Site, Burlington, Massachusetts, United States

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

Phase 3
Completed
Conditions
Chronic Hand Eczema
Interventions
Drug: Toctino
First Posted Date
2022-02-28
Last Posted Date
2025-05-09
Lead Sponsor
LEO Pharma
Target Recruit Count
513
Registration Number
NCT05259722
Locations
🇪🇸

LEO Pharma investigational site, Pontevedra, Spain

🇬🇧

LEO Pharma Investigational Site, Nottingham, United Kingdom

Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)

Phase 3
Completed
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2022-01-18
Last Posted Date
2025-03-11
Lead Sponsor
LEO Pharma
Target Recruit Count
136
Registration Number
NCT05194540
Locations
🇺🇸

LEO Pharma Investigational Site, Hialeah, Florida, United States

🇺🇸

LEO Pharma Investigator, Webster, Texas, United States

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Phase 1
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: LEO 138559 Placebo
First Posted Date
2021-10-29
Last Posted Date
2025-02-24
Lead Sponsor
LEO Pharma
Target Recruit Count
24
Registration Number
NCT05099133
Locations
🇺🇸

LEO Investigational Site, Los Angeles, California, United States

A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People

Early Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo capsule
First Posted Date
2021-09-20
Last Posted Date
2025-02-24
Lead Sponsor
LEO Pharma
Target Recruit Count
40
Registration Number
NCT05050279
Locations
🇬🇧

Labcorp Clinical Research Unit (CRU) Ltd, Springfield House, Hyde Street,, Leeds, United Kingdom

Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials

Phase 3
Completed
Conditions
Chronic Hand Eczema
Interventions
First Posted Date
2021-07-02
Last Posted Date
2025-04-08
Lead Sponsor
LEO Pharma
Target Recruit Count
801
Registration Number
NCT04949841
Locations
🇩🇰

LEO investigational Site, Copenhagen, Denmark

🇵🇱

LEO Pharma Investigational Site, Rzeszów, Poland

🇬🇧

LEO Investigational Sites, Redhill, Surrey, United Kingdom

and more 3 locations

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: LEO 138559 placebo
First Posted Date
2021-06-10
Last Posted Date
2025-03-13
Lead Sponsor
LEO Pharma
Target Recruit Count
58
Registration Number
NCT04922021
Locations
🇵🇱

LEO Pharma nvestigational Site, Rzeszów, Poland

🇵🇱

LEO Pharma Investigational Site, Wrocław, Poland

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2021-05-12
Last Posted Date
2025-02-24
Lead Sponsor
LEO Pharma
Target Recruit Count
108
Registration Number
NCT04883333
Locations
🇳🇱

LEO Pharma Investigational Site, Groningen, NZ, Netherlands

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema

Phase 3
Completed
Conditions
Chronic Hand Eczema
Interventions
Drug: Cream vehicle
First Posted Date
2021-05-04
Last Posted Date
2025-04-08
Lead Sponsor
LEO Pharma
Target Recruit Count
487
Registration Number
NCT04871711
Locations
🇬🇧

LEO Investigational Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath